luxurygasil.blogg.se

(NASDAQ:VERV) shares changed hands as the company’s beta touched 0.

Verve Therapeutics Inc does not currently pay a dividend.In the last trading session, 1.02 million Verve Therapeutics Inc. Analysts expect adjusted earnings to reach $-3.026 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was %. Over the past year the S&P 500 has gained 4.81% while VERB is down -87.99%.The Verve Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, …Verve Therapeutics Inc’s trailing 12-month revenue is $0.9 million with a % profit margin. VERB is higher by $0.09 from the previous closing price of $1.55 on volume of 107,892 shares. Verb Technology Company Inc (VERB) stock is up 6.1% while the S&P 500 is down -0.32% as of 1:29 PM on Thursday, May 11. Looking at the price targets, the low is -4.95% off current price level while to achieve the yearly. Analysts have given the company’s stock an average 52-week price target of $42.60, forecast between a low of $14.00 and high of $75.00. (VERV) has a beta value of 0, and an average true range (ATR) of 1.04. VERV lost -$2.91 per share the over the last 12 months.Further, Verve Therapeutics Inc. Over the past year the S&P 500 has risen 3.46% while VERV has risen 45.48%. VERV has risen $1.51 from the previous closing price of $16.21 on volume of 327,770 shares. NASDAQ:VERV Verve Therapeutics (VERV) News Today $16.24 -0.07 (-0.43%) (As of ET) Compare Today's Range $16.21 $16.93 50-Day Range $13.34 $20.16 52-Week Range $10.70 $43.00 Volume 348,607 shs Average Volume 621,793 shs Market Capitalization $1.01 billion P/E Ratio N/A Dividend Yield N/A Price Target $38.63 Verve Therapeutics Inc (VERV) stock is higher by 9.32% while the S&P 500 has fallen -0.21% as of 2:15 PM on Tuesday, May 9.(Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week. A fair number of Nasdaq-listed growth stocks moved higher this week.